Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management

Catheterization and Cardiovascular Interventions

Volumn 52, Issue 3, 2001, Pages 279-286

  Dippel, Eric J ^a   Kereiakes, Dean J ^a   Tramuta, Daniel A ^a   Broderick, Thomas M ^a   Shimshak, Thomas M ^a   Roth, Eli M ^a   Hattemer, Charles R ^a   Runyon, John P ^a   Whang, David D ^a   Schneider, John F ^a   Abbottsmith, Charles W ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Coronary perforation; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ALGORITHM; ANGIOGRAPHY; ARTERY RUPTURE; ARTICLE; BLEEDING; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; PERFORATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANGIOPLASTY, LASER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ATHERECTOMY, CORONARY; CINEANGIOGRAPHY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY VESSELS; FEMALE; HEART INJURIES; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS;

EID: 0035120443     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1065     Document Type: Article

References (27)

1. Transluminal coronary angioplasty complicated by coronary artery perforation
2. Coronary arterial rupture during coronary angioplasty
3. Perforations after percutaneous coronary intervention: Clinical, angiographic, and therapeutic observations
4. Increased coronary perforation in the new device era: Incidence, classification, management, and outcome
5. Coronary artery perforation during excimer laser coronary angioplasty
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
9. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
10. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
11. Management of coronary artery rupture: Covered stent or microcoiled embolization
12. The new coronary stent graft JoStent: First clinical experience
13. Stents wrapped in autologous vein: An experimental study
14. Implantation of stents covered by autologous arterial grafts in human coronary arteries: A new technique
15. Perfusion balloon catheter
16. Allergic reactions during anesthesia
17. Administration of protamine after coronary stent deployment
18. Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients underoing percutaneous intervention
19. Multicentric evaluation of heparinase on apTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor
20. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery, from GP IIb/IIIa receptor blockade
21. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
22. Reversal of the effects of C7E3 Fab treatment by platelet transfusion in cynomolgus monkeys
23. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab
24. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery
25. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
26. Efficacy of abciximab induced platelet blockade using a rapid point of care assay
27. Oral platelet GP IIb/IIIa blockade